Tremelimumab
About
Therapy type: Immunotherapy
Therapy strategy: CTLA-4 inhibition
Mappings
NCI Thesaurus: Tremelimumab (coding:ncit:C49085)
RxNorm: tremelimumab (coding:rxcui:2619313, coding:omop:741851)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| FDA (4) | Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Carboplatin, Durvalumab, Pemetrexed, Tremelimumab | |
| FDA (4) | Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Cisplatin, Durvalumab, Pemetrexed, Tremelimumab | |
| FDA (4) | Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Carboplatin, Durvalumab, Gemcitabine, Tremelimumab | |
| FDA (4) | Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Cisplatin, Durvalumab, Gemcitabine, Tremelimumab | |
| FDA (4) | Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Carboplatin, Durvalumab, Nab-paclitaxel, Tremelimumab | |
| EMA (2) | Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Carboplatin, Durvalumab, Tremelimumab |